Levetiracetam Extended-release
NDC Package 40051-079-11

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Levetiracetam Extended-release is a . Marketed by Lotus Pharmaceutical Co., Ltd. Nantou Plant, this product is identified by NDC 40051-079 and is authorized under FDA application ANDA202095.

Identification & Billing

NDC Package Code
40051-079-11
Package Description
60 TABLET in 1 BOTTLE
Product Code
40051-079
11-Digit Billing Format
40051007911

Clinical Specifications

Proprietary Name
Levetiracetam Extended-release
Dosage Form
-

Regulatory & Marketing

Labeler Name
Lotus Pharmaceutical Co., Ltd. Nantou Plant
FDA Application #
ANDA202095
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
10-31-2016
End Marketing Date
11-15-2019
Listing Expiration
11-15-2019
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 40051-079-11 identifies a specific commercial package of 60 tablet in 1 bottle of Levetiracetam Extended-release, labeled by Lotus Pharmaceutical Co., Ltd. Nantou Plant. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Lotus Pharmaceutical Co., Ltd. Nantou Plant on October 31, 2016. The current certification is valid through November 15, 2019.

How is this Lotus Pharmaceutical Co., Ltd. Nantou Plant product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 40051007911. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
40051-079-11
11-Digit CMS (5-4-2)
40051-0079-11

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.